Search

Finafloxacin

Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

Bupranolol

Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

AZD3409

AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. … As of February 2007 the development of AZD3409 had been discontinued.

AV-COVID-19

As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).

Elotuzumab

Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. … Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

OSI-7836

OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. … It is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested.

Practolol

A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.

SBT-100

SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb). … It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]

19-norandrostenedione

After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. … In the body 19-norandrostenedione is rapidly metabolized into [nandrolone], also known as nortestosterone.